EXAI (Exscientia plc) רווח נקי למניה ב-12 החודשים האחרונים

Exscientia plc (EXAI) is implementing robotic compound synthesis systems to complement software modeling. Net income per share over the last four quarters demonstrates capital dynamics, where the value -1.52 describes the current level. Revenues are based on the licensing of the AI platform and drug royalties. Intelligent algorithms are accelerating the creation of cancer therapies, turning the company into a key partner for pharma behemoths.

This indicator measures the portion of net profit attributable to a single ordinary share over a rolling year. Growth in this value confirms capitalization efficiency, while the current level of -1.52 serves as a benchmark for assessing business valuation. By analyzing the 12-month net income per share trend, an investor determines the real pace of profitability. For Exscientia plc (EXAI), this trend reflects the monetization of AI technologies in drug discovery. The company's high authority in biotech makes this metric a key indicator of the commercial success of its innovations.